Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
AstraZeneca
Instituto do Cancer do Estado de São Paulo
Sun Yat-sen University
National Health Research Institutes, Taiwan
Bayer
Replimune Inc.
China Medical University, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
3D Medicines
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
University of Texas Southwestern Medical Center
Case Comprehensive Cancer Center
AstraZeneca
Daiichi Sankyo
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Georgetown University
Boehringer Ingelheim
National Health Research Institutes, Taiwan
Fudan University
Seagen Inc.
Genome & Company
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC
UNICANCER
Bayer
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
Abramson Cancer Center at Penn Medicine
Jazz Pharmaceuticals
Peking Union Medical College Hospital
Peking Union Medical College Hospital
The Second Affiliated Hospital of Shandong First Medical University
National Institutes of Health Clinical Center (CC)
Institut Bergonié
Tongji Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Massachusetts General Hospital
The Second Affiliated Hospital of Shandong First Medical University
Eli Lilly and Company
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu HengRui Medicine Co., Ltd.
University of Pittsburgh
AHS Cancer Control Alberta
Shandong Cancer Hospital and Institute